KR950016729A - 유방 질환의 억제 방법 - Google Patents

유방 질환의 억제 방법 Download PDF

Info

Publication number
KR950016729A
KR950016729A KR1019940034920A KR19940034920A KR950016729A KR 950016729 A KR950016729 A KR 950016729A KR 1019940034920 A KR1019940034920 A KR 1019940034920A KR 19940034920 A KR19940034920 A KR 19940034920A KR 950016729 A KR950016729 A KR 950016729A
Authority
KR
South Korea
Prior art keywords
compound
breast disease
formula
inhibit breast
hexamethyleneimino
Prior art date
Application number
KR1019940034920A
Other languages
English (en)
Inventor
죠세프 세일즈 제임스
죠세프 컬리난 죠지
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950016729A publication Critical patent/KR950016729A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

하기 일반식( I )의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물의 효과량을 유방 질환의 치료를 필요로 하는 인간에게 투여하는 유방 질환 억제 방법:
상기식에서,
R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고: R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 구성되는 그룹중에서 선택된다.

Description

유방 질환의 억제 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 유방 질환 억제용 하기 일반식( I )의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고: R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 구성되는 그룹중에서 선택된다.
  2. 재1항에 있어서, 하이드로클로라이드 염 형태인 화합물.
  3. 제1항에 있어서, 예방적으로 투여하는 화합물.
  4. 제1항에 있어서, 하기 구조식 또는 그의 하이드로클로라이드 염인 화합물:
  5. 제1항에 있어서, 상기 유방 질환이 여성화 유방증, 유즙분비과다증, 비-섬유 낭포성, 비-암성 유방통 및 유선증에서 선택되는 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940034920A 1993-12-21 1994-12-19 유방 질환의 억제 방법 KR950016729A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/171,955 1993-12-21
US08/171,955 US5593987A (en) 1993-12-21 1993-12-21 Methods of inhibiting breast disorders

Publications (1)

Publication Number Publication Date
KR950016729A true KR950016729A (ko) 1995-07-20

Family

ID=22625779

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940034920A KR950016729A (ko) 1993-12-21 1994-12-19 유방 질환의 억제 방법

Country Status (15)

Country Link
US (1) US5593987A (ko)
EP (1) EP0659419A1 (ko)
JP (1) JPH07196501A (ko)
KR (1) KR950016729A (ko)
CN (1) CN1108100A (ko)
AU (1) AU701701B2 (ko)
CA (1) CA2138501A1 (ko)
CZ (1) CZ321294A3 (ko)
HU (1) HUT71480A (ko)
IL (1) IL112039A (ko)
NO (1) NO944933L (ko)
NZ (1) NZ270170A (ko)
PH (1) PH31326A (ko)
RU (1) RU2126251C1 (ko)
ZA (1) ZA9410088B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
PT1175433E (pt) 1999-05-04 2005-11-30 Strakan Int Ltd Glicosidos androgenos e sua actividade androgenica
US20020016318A1 (en) * 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
ITMI20011495A1 (it) * 2001-07-12 2003-01-12 Pharmaproducts Uk Ltd Sali di calcio ad attivita' citotossica
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
ITMI20041279A1 (it) * 2004-06-24 2004-09-24 Pharmaproducts Uk Ltd Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001242A (en) * 1974-08-02 1977-01-04 Eli Lilly And Company D-6-methyl-8-formyl-10α-alkoxy-8-ergolene
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5227375A (en) * 1990-02-08 1993-07-13 Endorecherche, Inc. Aromatase inhibitors
FR2677027B1 (fr) * 1991-05-27 1993-09-10 Roussel Uclaf Nouveaux produits sterouides substitues en position 6, et comportant, en position 10, un radical thioethyle, leur procede de preparation leurs intermediaires, leur application comme medicaments.
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
US5593987A (en) 1997-01-14
ZA9410088B (en) 1996-06-19
CA2138501A1 (en) 1995-06-22
RU94045280A (ru) 1996-10-10
EP0659419A1 (en) 1995-06-28
JPH07196501A (ja) 1995-08-01
NO944933D0 (no) 1994-12-19
HU9403666D0 (en) 1995-02-28
NO944933L (no) 1995-06-22
IL112039A0 (en) 1995-03-15
HUT71480A (en) 1995-11-28
CZ321294A3 (en) 1995-08-16
RU2126251C1 (ru) 1999-02-20
PH31326A (en) 1998-07-06
IL112039A (en) 1999-03-12
AU701701B2 (en) 1999-02-04
CN1108100A (zh) 1995-09-13
NZ270170A (en) 1997-07-27
AU8156094A (en) 1995-06-29

Similar Documents

Publication Publication Date Title
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950016744A (ko) 트롬빈을 저해하는 방법
KR950010893A (ko) 자궁내막증 억제 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
RU97108050A (ru) Способ ингибирования состояний, связанных с нейропептидом y
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950016729A (ko) 유방 질환의 억제 방법
KR950010890A (ko) 폐경기 증후군의 치료방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR940005270A (ko) 뼈 손실 예방에 유용한 벤조티오펜
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950016722A (ko) Ldl 산화 및 죽상동맥경화증의 억제 방법
KR950016735A (ko) 터너 증후군의 억제 방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid